GS starts Abivax at 'buy,' sees multibillion sales potential for lead drug candidate

Abivax SA

10/09/2026 08:05

** Goldman Sachs initiates coverage of French biotech company Abivax ABVX.PA with a "buy" rating, highlighting the multibillion revenue potential of its key drug obefazimod
** It says the clinical profile of the oral pill is de-risked by late-stage data for ulcerative colitis, an inflammatory bowel disease, addressing unmet medical needs
** The broker views the drug as a "multiblockbuster" opportunity within inflammatory bowel disease (IBD), and models €4 billion ($4.65 billion) in peak sales for ulcerative colitis as it offers biologic-like efficacy
** GS sees further potential in treating Crohn's disease, another bowel inflammation, projecting €3.5 billion in peak sales with mid-stage trial data expected in mid-2027
** The "buy" rating implies a 31% upside potential for the shares, which compares favourably to an average upside of 15% across the broker's European biotech coverage
** Out of nine analysts that cover Abivax, eight rate the stock "strong buy" or "buy"​ and one analyst rates "hold" - LSEG data
** Shares are up 3.5% in early Paris trading
($1 = 0.8593 euros)

(Reporting by Lucie Barbier in Gdansk)
((lucie.barbier@thomsonreuters.com))